Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:28 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma
NCT02587650 · University of California, San Francisco · PHASE2 · terminated · last registry update 2020-01-27 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Funding” | – | Registry record, University of California, San Francisco |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against MET within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-11-17Phase 3 first posted: Qilu Pharmaceutical Co., Ltd., WX-0593 Tablets + crizotinib (NCT04632758)
- 2020-10-27Phase 3 first posted: Hoffmann-La Roche, Entrectinib + Crizotinib (NCT04603807)
- 2020-10-14Phase 3 first posted: Merck Sharp & Dohme LLC, Belzutifan + Lenvatinib (NCT04586231)
- 2020-09-04Phase 3 first posted: Janssen Research & Development, LLC, Amivantamab + Pemetrexed (NCT04538664)
- 2020-09-04Results posted on the registry: National Cancer Institute (NCI), Cabozantinib S-malate (NCT02243605)
- 2020-07-27Phase 3 first posted: Janssen Research & Development, LLC, Amivantamab + Osimertinib (NCT04487080)
- 2020-07-15Phase 3 first posted: Hoffmann-La Roche, Cabozantinib + Atezolizumab (NCT04471428)
- 2020-07-14Results posted on the registry: National Cancer Institute (NCI), Cabozantinib S-malate (NCT01935934)
- 2020-07-10Results posted on the registry: AstraZeneca, Savolitinib + Sunitinib (NCT03091192)
- 2020-06-24Phase 3 first posted: Exelixis, Cabozantinib + Atezolizumab (NCT04446117)
- 2020-06-11Phase 3 first posted: Novartis Pharmaceuticals, Capmatinib + Docetaxel (NCT04427072)
- 2020-04-08Phase 3 first posted: Hoffmann-La Roche, Atezolizumab + Cabozantinib (NCT04338269)
- 2019-12-26Phase 3 first posted: Loxo Oncology, Inc., Selpercatinib + Cabozantinib (NCT04211337)
- 2019-07-11Results posted on the registry: Hoffmann-La Roche, Alectinib + Crizotinib (NCT02838420)
- 2019-05-03Phase 3 first posted: Exelixis, Cabozantinib + Nivolumab (NCT03937219)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision